CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

“We’re bringing impactful new science to this year’s AAD meeting, with new data on Nemluvio – our treatment for prurigo nodularis and atopic dermatitis – and the latest from our ...

Morgan Stanley has initiated Celldex Therapeutics (NASDAQ:CLDX) at overweight saying that barzolvolimab (barzol), its asset ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and ...

About Povorcitinib Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as Phase 2 ...

Hidradenitis suppurativa is an acne-like condition that causes painful bumps and lesions in and under the skin.

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the American Academy of Dermatology Annual Meeting.Ruxolitinib cream is a ...